FDA Draft Guidance On Drug Development For Early Alzheimer's A Call For Action On Biomarkers

FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease offers options for trial design, but without biomarkers to accurately diagnose the disease and track its progression, a trial could be doomed from the start.